VYNE Therapeutics jumps as skin disorder treatment shows promise

YARROW BIOSCIENCE

30/03/2023 13:37

** Shares of drug developer VYNE Therapeutics Inc  VYNE.O 
rise 11.75% to $2.9 before the bell
    ** Co says early stage study of its experimental drug to
treat skin disorder showed no evidence of low or lower platelet
counts at any time point for any dose cohort
    ** Adds its drug, VYN201, belongs to a subunit of BET class
of drug inhibitors, which can lead to potential clinical safety
concerns such as low platelet count
    ** Study showed the drug was safe and well-tolerated in
healthy individuals, and no dose adjustments were required
during trial
    ** Based on early stage data, enrollment of patients with
skin disorder, vitiligo for the second phase of early stage
study is ongoing and results are expected in mid-2023
    ** As of last close, VYNE down ~4% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))